Buscar en
Revista Colombiana de Reumatología
Toda la web
Inicio Revista Colombiana de Reumatología Test de respiración única para la capacidad de difusión de monóxido de carbo...
Información de la revista
Vol. 18. Núm. 2.
Páginas 96-108 (Junio 2011)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 18. Núm. 2.
Páginas 96-108 (Junio 2011)
DOI: 10.1016/S0121-8123(11)70125-6
Acceso a texto completo
Test de respiración única para la capacidad de difusión de monóxido de carbono (DLCO) y su interpretación en enfermedades autoinmunes. Aplicación en la práctica clínica -Segunda Parte-
Single breath carbon monoxide diffusing capacity (DLCO) test and its interpretation in autoimmune diseases. Application in clinical practice - Part II -
Visitas
...
Sergio Alexander Mora Alfonso1,
Autor para correspondencia
sergiomora3@hotmail.com

Correspondencia: Unidad de Reumatología – Medicina Interna, Hospital Universitario de La Samaritana Piso 5, carrera 8 No 0-55, Bogotá, Colombia.
, Juan Manuel Bello Gualtero1, John Londoño2, Rafael Raúl Valle-Oñate3, Gerardo Quintana4
1 Médico Internista, Reumatólogo, Universidad Militar Nueva Granada. Hospital Militar Central y Hospital Universitario de La Samaritana (E.S.E)
2 Médico Internista, Reumatólogo, Servicio Reumatología. Hospital Militar Central. Universidad de la Sabana, Grupo de Investigación de Espondiloartropatías
3 Médico Internista, Reumatólogo, Profesor titular de Reumatología Universidad Militar Nueva Granada, Jefe servicio de Reumatología Hospital Militar Central, Bogotá
4 Médico Internista, Reumatólogo y Epidemiólogo Clínico, Departamento de Medicina, Facultad de Medicina, Universidad Nacional de Colombia y Universidad de los Andes, y Servicio de Reumatología, Fundación Santa Fe de Bogotá
Información del artículo
Resumen

El test de respiración única ha probado por si mismo ser una parte esencial del tamizaje de rutina de la función pulmonar, y de igual valor que la espirometría. A pesar de 100 años de investigación, aún no existe certeza sobre la relativa importancia de las membranas alveolo-capilares vs los eritrocitos como los pasos que sean delimitantes en el transporte global del monóxido de carbono del gas hacia la sangre, pero esto es solo un problema cuantitativo. La naturaleza esencial del test de DLCO ya ha sido elucidada, siendo F.J.W. Roughton y R.E. Forster los mayores protagonistas en esta descripción.

La interpretación de la DLCO, en conjunto con la espirometría y los volúmenes pulmonares, pueden contribuir en la evaluación de enfermedades pulmonares subyacentes y, en el campo reumatológico es esencial su conocimiento puesto que ofrece la posibilidad de establecer un diagnóstico diferencial y un seguimiento cercano de los pacientes con enfermedades autoinmunes con manifestaciones pulmonares. El test de espiración única para la capacidad de difusión de monóxido de carbono, la espirometría y los gases arteriales son los test de función pulmonar más ampliamente utilizados para la evaluación y tratamiento de pacientes.

Palabras clave:
intercambio de gases
membrana
difusión
test de respiración única para la capacidad de difusión de monóxido de carbono
(DLCO)
pruebas de función pulmonar
enfermedades autoinmunes
Summary

The single breath DLCO (TLCO) has proved as an essential part of the routine pulmonary function screen, similar to spirometry. In spite of nearly 100 years research, there is still concern over the relative importance of the alveolarcapillary membranes versus the red cells as rate limiting steps in the overall transfer of carbon monoxide from gas to blood, but this is only a quantitative problem. The essential nature of the DLCO has already been elucidated by F.J.W. Roughton and R.E. Forster having played the major roles.

Interpreting the DLCO, in conjunction with spirometry and lung volumes assessment, may assist in diagnosing the underlying disease and in the Rheumatology field it is essential it’s knowledge because it offers the possibility of establish the differential diagnosis and a close follow-up of the patients with pulmonary manifestations in autoimmune diseases.

Key words:
gas exchange
pulmonary
membrane
diffusion
single-breath carbon monoxide diffusing capacity
(DLCO)
pulmonary function tests
autoimmune diseases
El Texto completo está disponible en PDF
Referencias
[1.]
American Thoracic, Society, Single-breath carbon monoxide diffusing capacity (Transfer factor).
Recommendations for a standard technique-1995 update.
Am J Respir Crit Care Med, 152 (1995), pp. 2185-2198
[2.]
R.L. Jensen, R.O. Crapo.
Diffusing Capacity: How to get it right.
Respir Care, 48 (2003), pp. 777-782
[3.]
E.W. Glissmeyer, R.L. Jensen, R.O. Crapo, L.W. Greenway.
Initial testing with a carbon monoxide diffusing capacity simulator.
J Investig Med, 47 (1999),
[4.]
R.O. Crapo, R.L. Jensen.
Standards and interpretive issues in lung function testing.
Respir Care, 48 (2003), pp. 764-772
[5.]
R. Pellegrino, G. Viegi, V. Brusasco, R.O. Crapo, F. Burgos, R. Casaburi, A. Coates.
Interpretative strategies for lung function tests.
Eur Respir J, 26 (2005), pp. 948-968
[6.]
Madama, C. Vincent.
Pulmonary Function Testing and Cardiopulmonary Stress Testing. Tests for Pulmonary Gas Diffusion.
Ed Delmar Publisher, (1998),
[7.]
AARC, Clinical Practice Guideline. Single breath Diffusing Capacity UPDATE. 1999; 4:533–546.
[8.]
Chinn, et al.
Transfer factor (diffusing capacity) standardized for alveolar volume: reference values and application of a new linear model to replace KCO.
Eur Respir J, 9 (1996), pp. 1269-1277
[9.]
J. Hughes, N. Pride.
In defense of the carbon monoxide transfer coefficient KCO (TL/VA).
Eur Respir J, 17 (2001), pp. 168-174
[10.]
C. Connie, M. Hsia.
Recruitment of lung diffusion capacity.
Chest, 122 (2002), pp. 1774-1783
[11.]
N. MacIntyre, R.O. Crapo, et al.
Standardization of the single-breath determination of carbon monoxide uptake in the lung.
Eur Respir J, 26 (2005), pp. 720-735
[12.]
L.C. Kanengiser, D.M. Rapoport, H. Epstein, R.M. Goldring.
Volume adjustment of mechanics and diffusion in interstitial lung disease: lack of clinical relevance.
Chest, 96 (1989), pp. 1036-1042
[13.]
Hilary C. Cain, Paul W. Noble, Richard A. Matthay.
Pulmonary manifestations of Sjögren's syndrome.
Clinics in Chest Medicine, 19 (1998),
[14.]
N. Sutcliffe, T. Stoll, S. Pyke, et al.
Functional disability and end organ damage in patients with systemic lupus erythematosus (SLE), SLE and Sjogren's syndrome (SS), and primary SS.
J Rheumatol, 25 (1988), pp. 63-68
[15.]
C. Kelly, P. Gardiner, B. Pal, et al.
Lung function in primary Sjögren's syndrome: A cross sectional and longitudinal study.
Thorax, 46 (1991), pp. 180-183
[16.]
M. Linstow, N.J. Kriegbaum, V. Backer, et al.
A followup study of pulmonary function in patients with primary Sjögren's syndrome.
Rheumatol Int, 10 (1990), pp. 47-49
[17.]
P. Mialon, L. Barthelelemy, P. Sebert, et al.
A longitudinal study of lung impairment in patients with primary Sjogren's syndrome.
Clin Exp Rheumatol, 15 (1997), pp. 349-354
[18.]
B. Wallaert, P.-Y. Hatron, J.M. Grosbois, et al.
Subclinical pulmonary involvement in collagen-vascular diseases assessed by bronchoalveolar lavage. Relationship between alveolitis and subsequent changes in lung function.
American Review of Respiratory Diseases, 133 (1986), pp. 574-580
[19.]
F. Salaffi, M. Manganelli, M. Carotti, et al.
A longitudinal study of pulmonary involvement in primary Sjögren’s syndrome: relationship between alveolitis and subsequent lung changes on high-resolution computed tomography.
Brit J Rheumatol, 37 (1998), pp. 263-269
[20.]
A. Lahdensuo, M. Korpela.
Pulmonary findings in patients with primary Sjögrens’syndrome.
Chest, 108 (1995), pp. 316-319
[21.]
M.B. Bolster, R.M. Silver.
Lung disease in systemic sclerosis (scleroderma).
Bailliere's Clinical Rheumatology, 7 (1993), pp. 79-97
[22.]
G.R. Owens, G.J. Fino, D.L. Herbert, et al.
Pulmonary function in progressive systemic sclerosis. Comparison of CREST syndrome variant with diffuse scleroderma.
Chest, 84 (1983), pp. 546-550
[23.]
P.K. Adhikari, F.A. Bianchi, S.F. Boushy, et al.
Pulmonary function in scleroderma: Its relation to changes in chest roentgenogram and in the skin of the thorax.
American Review of Respiratory Disease, 86 (1962), pp. 823-831
[24.]
L.R. Bagg, D.T.D. Hughes.
Serial pulmonary function tests in progressive systemic sclerosis.
Thorax, 34 (1979), pp. 224-228
[25.]
A. Scheja, A. Akesson, P. Wollmer, et al.
Early pulmonary disease in systemic sclerosis: A comparison between carbon monoxide transfer factor and static lung compliance.
Ann Rheum Dis, 52 (1993), pp. 725-729
[26.]
M. Catterall, N.R. Rowell.
Respiratory function in progressive systemic sclerosis.
Thorax, 18 (1963), pp. 10-15
[27.]
G.R. Owens, G.J. Fino, D.L. Herbert, et al.
Pulmonary function in progressive systemic sclerosis. Comparison of CREST syndrome variant with diffuse scleroderma.
Chest, 84 (1983), pp. 546-550
[28.]
R.H. Young, G.J. Mark.
Pulmonary vascular changes in scleroderma.
Am J Med, 64 (1978), pp. 998-1004
[29.]
A.M. Stupi, V.D. Steen, G.R. Owens, et al.
Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis.
Arthritis Rheum, 29 (1986), pp. 515-524
[30.]
R.D. Altman, T.A. Medsger Jr., D.A. Bloch, et al.
Predictors of survival in systemic sclerosis (scleroderma).
Arthritis Rheum, 34 (1991), pp. 403-413
[31.]
M. Peters-Golden, R.A. Wise, M.C. Hochberg, et al.
Carbon monoxide diffusing capacity as a predictor of outcome in systemic sclerosis.
Am J Med, 77 (1984), pp. 1027-1034
[32.]
Z. Dujic, D. Eterovic, J. Tocilj, et al.
Increase of pulmonary diffusing capacity in systemic sclerosis.
Br J Rheumatol, 33 (1994), pp. 437-441
[33.]
D.S. McCarthy, F.D. Baragar, S. Dhingra, et al.
The lung in systemic sclerosis (scleroderma): A review and new information.
Semin Arthritis Rheum, 17 (1988), pp. 271-283
[34.]
R.M. Silver.
Scleroderm. Clinical problems. The lungs.
Rheum Dis Clin North Am, 22 (1996), pp. 825-840
[35.]
C. Harmon, F. Wolfe, S. Lillard, et al.
Pulmonary involvement in mixed connective tissue disease (MCTD).
Arthritis Rheum, 19 (1976), pp. 801
[36.]
G.C. Sharp, P.C. Anderson.
Current concepts in the classification of connective tissue diseases. Overlap syndromes and mixed connective tissue disease (MCTD).
J Am Acad Dermatol, 2 (1980), pp. 269-279
[37.]
G.C. Sharp, B.H. Singsen.
Mixed connective tissue disease.
Arthritis and Allied Conditions: A Textbook of Rheumatology, ed 11, pp. 1080-1091
[38.]
W.D. Sullivan, D.J. Hurst, C.E. Harmon, et al.
A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease.
Medicine, 63 (1984), pp. 92-107
[39.]
S.S. Derderian, C.J. Tellis, P.H. Abbrecht, et al.
Pulmonary involvement in mixed connective tissue disease.
Chest, 88 (1985), pp. 45-48
[40.]
S.M. Sant, M. Doran, H.M. Fenelon, E.S. Breatnach.
Pleuropulmonary abnormalities in patients with systemic lupus erythematosus: assessment with high resolution computed tomography, chest radiography and pulmonary function tests.
Clin Exp Rheumatol, 15 (1997), pp. 507-513
[41.]
S.L. Silberstein, P. Barland, A.I. Grayzel, S.K. Koerner.
Pulmonary dysfunction in systemic lupus erythematosus: prevalence, classification and correlation with other organ involvement.
J Rheumatol, 7 (1980), pp. 187-195
[42.]
T.W. Chick, R.J. de Horatius, B.E. Skipper, R.P. Messner.
Pulmonar dysfunction in systemic lupus erythematosus without pulmonary symptoms.
J Rheumatol, 3 (1976), pp. 262-268
[43.]
A. Andonopoulos, S. Constantopoulos, V. Galanopoulou, A.A. Dronos, N.C. Acritidis, H.M. Moutsopoulos.
Pulmonary function of nonsmoking patients with systemic lupus erythematosus.
Chest, 94 (1988), pp. 312-315
[44.]
M. Nakano, H. Hasegawa, T. Takada, S. Ito, Y. Muramatsu, M. Satoh, E. Suzuki, F. Gejyo.
Pulmonary diffusion capacity in patients with systemic lupus erythematosus.
Respirology, 7 (2002), pp. 45-49
Copyright © 2011. Asociación Colombiana de Reumatología
Opciones de artículo
Herramientas